BC Week In Review | Apr 27, 2018
Company News

UCB buys rights to seizure candidate

UCB S.A. (Euronext:UCB) acquired rights to intranasal midazolam (USL261) from the Proximagen LLC subsidiary of Acova Inc. (Plymouth, Minn.). Proximagen will receive $150 million up front and is eligible for $220 million in milestones. The...
Company News | Apr 20, 2018
Company News

UCB buys rights to seizure candidate

UCB S.A. (Euronext:UCB) acquired rights to intranasal midazolam (USL261) from the Proximagen LLC subsidiary of Acova Inc. (Plymouth, Minn.). Proximagen will receive $150 million up front and is eligible for $220 million in milestones. The...
BC Week In Review | Oct 19, 2015
Company News

Cardiome, Mitsubishi Tanabe Pharma deal

Cardiome and Mitsubishi’s Mitsubishi Pharma Europe Ltd. subsidiary partnered to co-promote Cardiome’s Aggrastat tirofiban and Mitsubishi’s Exembol argatroban in the U.K. for a three-year term. Each company will promote the other company’s product to the...
BC Innovations | Feb 27, 2014
Targets & Mechanisms

The XII factor

Factor XII sits atop one branch of the clotting cascade but has not been pursued for treating and preventing thrombosis because it was seen as a minor player in blood coagulation. Now, a group from...
BC Innovations | Nov 21, 2013
Targets & Mechanisms

Riding the integrin wave in thrombosis

The use of platelet integrin a 2b b 3 inhibitors in thrombosis, while clinically very effective, is associated with a high risk of bleeding that has limited their use. Now, researchers at the University of...
BC Week In Review | Sep 2, 2013
Clinical News

Exembol argatroban regulatory update

The Scottish Medicines Consortium (SMC) reversed its November 2012 decision and now recommends the use of Exembol argatroban from Mitsubishi on the National Health Service (NHS) in Scotland for anticoagulation in adult patients with heparin-induced...
BC Week In Review | Apr 15, 2013
Clinical News

Novastan argatroban small molecule thrombin inhibitor data

In a Phase III trial of Novastan as an anticoagulant in patients with a history of allergic reaction to heparin, all 30 patients met the primary end point of completing the surgical procedure (either angioplasty,...
BC Week In Review | Apr 15, 2013
Clinical News

Texas Biotech regulatory update

The FDA granted priority review status for TBX's NDA for its Novastan ( argatroban ) thrombin inhibitor. TBX and SmithKline-Beecham (Philadelphia, Penn.) last month agreed to market and co-develop Novastan in the U.S. and Canada as an...
BC Week In Review | Jul 16, 2012
Company News

Mitsubishi Tanabe Pharma sales and marketing update

Mitsubishi's Mitsubishi Pharma Europe Ltd. subsidiary launched Exembol argatroban in the U.K. to treat heparin-induced thrombocytopenia. The price is £248.5 ($384.83) per 250 mg vial. The recommended starting dose is 2 µg/kg/minute. The synthetic thrombin...
BioCentury | Sep 22, 2008
Strategy

Biovitrum marketed products

Biovitrum marketed products Product Description Indication Partner Aloxi palonosetron (A) Selective serotonin (5-HT3) receptor antagonist Prevent chemotherapy induced nausea and vomiting (CINV)- Helsinn Healthcare BeneFIX Recombinant coagulation Factor IX Hemophilia B Wyeth (NYSE:WYE) Kepivance palifermin...
Items per page:
1 - 10 of 62